Anavex Life Sciences (AVXL) was up 9.3% after the company said it is looking to accelerate clinical studies of treatments for Alzheimer's and Parkinson's disease by teaming up with Ariana Pharma and using its KEM patient stratification technology. The biopharmaceutical company said Wednesday it is hoping to use the KEM technology to speed up its phase 2/3 of the ANAVEX 2-73 study for Alzheimer's clinical development. KEM is a system that allows users to analyze datasets at rapid speeds, while identifying certain trends within the data.
... In addition, what we’ve been learning from CNS-based studies, whether AD or MS, is that the data are complex across multiple endpoints. As such, having the KEM system with Ariana in place to help analyze complex data is, in our view, a strategic positive for Anavex,” Kolbert concludes.